中药联合EGFR-TKI治疗EGFR突变阳性晚期肺腺癌的多中心随机双盲安慰剂对照试验
结果显示联合中药组中位无进展生存期显著延长(13.50个月 vs 10.94个月,HR 0.68,P=0.0064),客观缓解率和生活质量亦获改善,且1-2级药物相关不良事件较少。
要点
- 中药联合EGFR-TKI较单用TKI显著延长中位PFS(13.50 vs 10.94个月,HR 0.68)。
- 联合中药显著提高客观缓解率(64.32% vs 52.66%,P=0.026)并改善生活质量。
- 联合中药组药物相关1-2级不良事件较少,一线治疗亚组获益更明显。
核心结论
- 在EGFR突变阳性晚期非小细胞肺癌患者中,EGFR-TKI联合中药较单用TKI显著延长中位无进展生存期。
研究设计与样本
- EGFR-TKI包括厄洛替尼150 mg/d、吉非替尼250 mg/d或埃克替尼125 mg tid/d,主要终点为无进展生存期(PFS)。
主要发现
- TKI+中药组中位PFS为13.50个月(95%CI 11.20-16.46),TKI+安慰剂组为10.94个月(95%CI 8.97-12.45),HR 0.68(95%CI 0.51-0.90),P=0.0064。
- 亚组分析显示一线治疗获益更明显(15.97 vs 10.97个月,P=0.0447),二线治疗差异未达统计学显著(11.43 vs 9.23个月,P=0.0530)。
- 外显子19缺失患者PFS显著长于21 L858R患者。
- 联合中药显著提高客观缓解率(64.32% vs 52.66%,P=0.026)并改善生活质量(FACT-L和LCSS评估)。
- 联合中药组药物相关1-2级不良事件较少见。
关键数值与推荐
- 中位PFS:TKI+中药组13.50个月(95%CI 11.20-16.46) vs TKI+安慰剂组10.94个月(95%CI 8.97-12.45),HR 0.68(95%CI 0.51-0.90),P=0.0064。
- 客观缓解率:TKI+中药组64.32% vs TKI+安慰剂组52.66%,P=0.026。
- 一线治疗亚组中位PFS:15.97 vs 10.97个月,P=0.0447;二线治疗亚组:11.43 vs 9.23个月,P=0.0530。
临床怎么用
- 对于EGFR突变阳性晚期肺腺癌患者,可考虑在EGFR-TKI治疗基础上联合中药以延长PFS并提高客观缓解率。
- 一线治疗患者联合中药的PFS获益更明显,二线治疗需个体化评估。
- 联合中药可能减少药物相关1-2级不良事件,但需监测安全性。
局限性
- 二线治疗亚组PFS差异未达统计学显著(P=0.0530)。
- 外显子19缺失与21 L858R亚组间PFS差异的具体数值未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: To determine the clinical activity and safety of Chinese herbal medicine (CHM) combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in patients with advanced pulmonary adenocarcinoma (ADC) and the ability of CHM combined with EGFR-TKI to activate EGFR mutations. Methods: Three hundred and fifty-four patients were randomly assigned to EGFR-TKI (erlotinib 150 mg/d, gefitinib 250 mg/d, or icotinib 125 mg tid/d) plus CHM (TKI+CHM, N = 185) or EGFR-TKI plus placebo (TKI+placebo, N = 169). Progression-free survival (PFS) was the primary end point; the secondary end points were overall survival (OS), objective response rate (ORR), disease control rate (DCR), quality of life [Functional Assessment of Cancer Therapy-Lung (FACT-L) and Lung Cancer Symptom Scale (LCSS)], and safety. Results: The median PFS was significantly longer for the TKI+CHM group (13.50 months; 95% CI, 11.20-16.46 months) than with the EGFR-TKI group (10.94 months; 95% CI, 8.97-12.45 months; hazard ratio, 0.68; 95% CI, 0.51-0.90; P = 0.0064). The subgroup analyses favored TKI+CHM as a first-line treatment (15.97 vs. 10.97 months, P = 0.0447) rather than as a second-line treatment (11.43 vs. 9.23 months, P = 0.0530). Patients with exon 19 deletion had a significantly longer PFS than with 21 L858R. The addition of CHM to TKI significantly improved the ORR (64.32% vs. 52.66%, P = 0.026) and QoL. Drug-related grade 1-2 adverse events were less common with TKI+CHM. Conclusions: TKI+CHM improved PFS when compared with TKI alone in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT01745302.
引用
- Jiao L, Xu J, Sun J, et al. Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Front Pharmacol. 2019. PMID: 31333456. doi:10.3389/fphar.2019.00732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。